Hemlibra 105mg Injection is a prescription medication used for the routine prophylactic treatment of Hemophilia A in adults and children. Its active ingredient is emicizumab, a bispecific antibody designed to mimic the function of Factor VIII, a clotting protein that is deficient in individuals with Hemophilia A. By bridging Factor IXa and Factor X, emicizumab facilitates the activation of Factor X, thereby promoting blood clot formation and reducing the frequency of bleeding episodes.
Hemlibra is administered subcutaneously and is typically given once a week or once every two weeks, depending on the prescribed dosage and the patient’s individual needs. It is crucial to follow the dosage instructions provided by a healthcare professional. Common side effects may include injection site reactions (redness, swelling, pain), headache, and joint pain. Less common but more serious side effects can occur, and patients should report any unusual symptoms to their doctor immediately. Hemlibra should be stored at room temperature and protected from light. Do not freeze.
